Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

Abstract Background Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its administration, and the underlying mechanism is still unclear. Methods Anlotinib resistant lung cancer cel...

Full description

Bibliographic Details
Main Authors: Jun Lu, Wei Xu, Jie Qian, Shuyuan Wang, Bo Zhang, Lele Zhang, Rong Qiao, Minjuan Hu, Yiming Zhao, Xiaodong Zhao, Baohui Han
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Medical Genomics
Subjects:
Anlotinib
Drug resistance
CXCL2
Non-Small Cell Lung Cancer
Transcriptome
Online Access:http://link.springer.com/article/10.1186/s12920-019-0482-y

Internet

http://link.springer.com/article/10.1186/s12920-019-0482-y

Similar Items